DeCure for Microcephaly, short stature, and limb abnormalities
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for microcephaly, short stature, and limb abnormalities — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMicrocephaly, short stature, and limb abnormalities maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for microcephaly, short stature, and limb abnormalities is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Four children with sporadic primary microcephaly, short stature, delayed bone age, and low growth velocity all had a normal growth hormone response to standard pharmacological tests, though one had reduced spontaneous nocturnal secretion. Regardless of those results, all four were treated with exogenous growth hormone and all showed an increase in growth rate. No data on final adult height, cognitive outcomes, or adverse effects were reported in that 1989 study.
A 1993 report described a mother and two sons with microcephaly, short stature, a distinctive face, broad thumbs and great toes, and mild developmental delay. The authors noted similarities to two earlier case reports but stated it was not certain whether the patients had the same condition. Inheritance was proposed as either autosomal or X-linked dominant. No treatment was tested.
A 2014 review of growth abnormalities in genetic syndromes listed chromosomal abnormalities (Down, Turner), monogenic syndromes (Noonan, Cornelia de Lange, SHOX abnormalities), and epigenetic disorders (Silver-Russell, Prader-Willi) as causes of short stature, but did not address microcephaly or limb abnormalities specifically. A separate 2014 review on regulation of body and brain size noted that mutations in centrosomal and spindle-formation genes can cause either microcephalic primordial dwarfism, pure primary microcephaly, or both, and described a homozygous MAP4 mutation in two siblings with severe growth retardation but normocephaly, attributed to compensatory MAP2 expression in brain.
A 2025 review on achondroplasia — a condition caused by an FGFR3 missense mutation, characterised by short stature, macrocephaly, and rhizomelic limb shortening — reported that vosoritide (Voxzogo), a C-type natriuretic peptide analogue, was approved by the US FDA and EMA in 2021 for children with achondroplasia. Other agents (TransCON CNP, meclozine, infigratinib, recifercept) were listed as undergoing clinical trials. No data from those trials were provided in the abstract. Achondroplasia is a distinct genetic disorder from the syndromes described in the other abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics · 1994 · 20 citations
Microcephalic osteodysplastic dysplasia
AbstractWe present two patients with a distinct facial phenotype, short stature, brachydactyly, clubfoot deformities, cataracts, microcephaly, and normal intelligence. Similar radiographic abnormalities of the spine, long bones, hands, and feet were noted. These patients are similar to 2 males previously described by Saul and Wilson [1990: Am J Med Genet 35:388-393]. These 4 patients appear to have a unique skeletal dysplasia characterized by microcephaly, distinct facial phenotype, multisystem abnormalities, and short stature of postnatal onset.
Archives of Pediatrics and Adolescent Medicine · 1989 · 7 citations
Growth Hormone Treatment in Children With Sporadic Primary Microcephaly
AbstractFour children with sporadic primary microcephaly associated with short stature, delayed bone age, and low growth velocity are described. All of the children showed a normal growth hormone response to standard pharmacological tests but one of the patients had a reduced spontaneous growth hormone nocturnal secretion. Regardless of the results of their somatotropic function evaluation, the patients were treated with exogenous growth hormone and all of them showed an increase in growth rate.
American Journal of Medical Genetics · 1993 · 3 citations
Distinctive autosomal or X‐linked dominant syndrome of microcephaly, mild developmental delay, short stature, and distinctive face
AbstractWe report on a mother and two sons with a syndrome of microcephaly, short stature, a distinctive face, broad thumbs and great toes, and mild developmental delay. There are similarities to the patients reported by Bawle and Horton [Am J Med Genet 33:382-384, 1989] and Evans [Clin Genet 39:178-180, 1991] but it is not certain whether the patients have the same condition. Inheritance could either be autosomal or X-linked dominant.
Cephalometric Evaluation of Children with Short Stature of Genetic Etiology. A Review
AbstractIntroduction: A plethora of biological molecules regulate chondrogenesis in the epiphyseal growth plate. Disruptions of quantity and function of these molecules can manifest clinically as stature abnormalities of various etiologies. Traditionally, the growth hormone/insulin-like growth factor 1 (IGF1) axis represents the etiological center of final stature attainment. Of note, little is known about the molecular events that dominate the growth of the craniofacial complex and its correlation with somatic stature. Aim: Given the paucity of the relevant data, this review discusses available information regarding potential applications of lateral cephalometric radiography as a potential clinical indicator of genetic short stature in children. Materials and Methods: A literature search was conducted in the PubMed electronic database using the key words: cephalometric analysis and short stature; cephalometric analysis and achondroplasia; cephalometric analysis and hypochondroplasia; cephalometric analysis and skeletal abnormalities; cephalometr* and SHOX; cephalometr* and CNP; cephalometr* and ACAN; cephalometr* and CNVs; cephalometr* and IHH; cephalometr* and FGFR3; cephalometr* and Noonan syndrome; cephalometr* and “Turner syndrome”; cephalometr* and achondroplasia. Results: In individuals with genetic syndromes causing short stature, linear growth of the craniofacial complex is confined, following the pattern of somatic short stature regardless of its etiology. The angular cephalometric measurements differ from the average height normal individuals and are suggestive of a posterior placement of the jaws and a vertical growth pattern of the face. Conclusion: The greater part of the existing literature regarding cephalometric measurements in short statured children with genetic syndromes provides qualitative data. Furthermore, cephalometric data for individuals affected with specific rare genetic conditions causing short stature, should be the focus of future studies. These quantitative data are required to potentially establish cut-off values to refer for genetic testing based on craniofacial phenotypes.
Growth Abnormalities Resulting in Short Stature in Genetic Syndromes
AbstractGrowth Abnormalities Resulting in Short Stature in Genetic Syndromes Short stature is a common problem in children and adolescents, and has been reported in a wide variety of genetic syndromes. In this article, we provide an overview of clinical features typical to handful genetic syndromes in which short stature is a cardinal feature, and for which there is a well based core data. These disorders include chromosomal abnormalities such as Down and Turner syndromes, monogenic syndromes (Noonan syndrome and other selected syndromes caused by RAS/MAPK pathway genes, Cornelia de Lange syndrome and SHOX gene abnormalities) and epigenetic mechanism abnormalities, including Silver-Russell syndrome and Prader-Willi syndrome.
Journal of Education Health and Sport · 2025 · 0 citations · open access
Advances in the treatment of achondroplasia
AbstractAbstract: Achondroplasia is a condition resulting from a missense mutation in the FGFR3 (fibroblast growth factor receptor 3) gene, representing the predominant etiology of short height in humans. Physical phenotypic characteristics encompass small stature, macrocephaly with frontal bossing, midface hypoplasia, rhizomelic shortening of the limbs, brachydactyly, and genu varum. Untreated cases result in several orthopedic and neurological issues that ultimately lead to impairment. Treatment techniques for achondroplasia can be categorized into surgical and pharmaceutical therapy. Enhanced comprehension of the etiology of this disease has prompted efforts to create causative pharmaceutical treatments. This review introduces innovative possible pharmacological therapies for achondroplasia including vosoritide, which received approval for patient usage in 2021, as well as TransCON CNP, meclozine, infigratinib, and recifercept, all now undergoing clinical trials. Aim of the study: The main aim of this study is to elucidate the most recent treatment methodologies for patients with achondroplasia. This article presents groundbreaking advancements and new therapies designed to enhance the quality of life for patients with achondroplasia, while also raising awareness of available treatment choices and fostering optimism for future developments in this domain. In 2021, vosoritide (Voxzogo), a C-type natriuretic peptide (CNP) analogue, was approved by the US FDA and EMA for use in children with achondroplasia. As of January 2025, vosoritide therapy has been available in Poland for patients with achondroplasia under the drug program, which is a response to the unmet therapeutic need in patients with achondroplasia. Materials and methods: A review of the literature available in the PubMed and Google Scholar databases was performed, using the key words: „achondroplasia", „FGFR3”, „skeletal dysplasia", „vosoritide”, „short stature”.
Regulation of body and brain size: role of MAP4 and other centrosomal proteins
AbstractGrowth is a complex phenomenon that is influenced by many factors in the genome and the environment. Both genetic defects as well as epigenetic changes have been identified in a broad spectrum of growth disorders. Disorders with growth failure typically result in short stature. Mutations in genes affecting bone and/or cartilage development usually cause disproportionate short stature phenotypes with either short limbs or short trunk, depending on which parts of the skeleton are most affected (the so-called skeletal dysplasias). The molecular pathogenesis of proportionate short stature is more diverse and includes chromosomal aberrations, imprinting defects and monogenic alterations. Large-scale genome-wide association studies of adult height have identified more than 180 loci that may influence linear growth. One particular and interesting group of genes are those that code for proteins that are necessary for centrosome and spindle formation during mitosis. Mutations in some of these genes can cause either (microcephalic) primordial dwarfism (e.g. PCNT, CEP63, PLK4), or pure forms of primary microcephaly (e.g. CEP135, WDR62, CDK5RAP2, STIL) or both (e.g. CENPJ, CEP152), illustrating the functional link between brain growth and body size. In this issue, Zahnleiter and co-authors (Hum Mutat 36:87–97, 2015) identified a homozygous hypomorphic mutation in a microtubule-associated protein (MAP4) in two siblings with severe growth retardation but normocephaly. The normal head size in the affected individuals was attributed to the predominant expression of the homologous MAP2 gene in the brain. Using immunofluorescence staining on patient fibroblasts, the authors could not only demonstrate supernumerary centrosomes during cell division but also abnormal ciliogenesis with shorter cilia and Golgi structures disconnected from the perinuclear space. This study expands the phenotypic spectrum of centrosomal defects causing growth failure. It also underscores the role of microtubular proteins not only in cell division but also in ciliogenesis and assembly of the Golgi apparatus.
Journal of Pediatric Endocrinology and Metabolism · 2023 · 0 citations
The benefit of rhGH therapy in a Chinese child with 12q14 microdeletion syndrome: a case report
AbstractOBJECTIVES: The 12q14 microdeletion syndrome is a rare genetic condition characterized by intrauterine growth restriction, proportionate short stature, failure to thrive, and intellectual disability. Few reports have discussed the therapeutic aspect of patients with 12q14 microdeletion syndrome. Herein, we report the first case of 12q14 microdeletion patient treated with rhGH without growth hormone deficiency. CASE PRESENTATION: The patient presented with feeding difficulties during infancy, failure to thrive, intellectual disability and subtle dysmorphic facial features. The patient first visited the clinic at 5 years and 3 months, his height was 91.4 cm (-4.9 SD) and weight 10.0 kg (-2.86 SD). The growth hormone level was within the normal range. Bone radiological testing revealed no significant abnormalities. Genetic analysis identified a 6.97 Mb deletion at the chromosome 12q14.1-q14.3 region in the proband. Recombinant human growth hormone therapy was initiated, which lasted for 12 months, and the new height was 101.0 cm (-4.0 SD) and weight 12.0 kg (-3.6 SD). CONCLUSIONS: This report first showed that patient with 12q14 microdeletion, although without growth hormone deficiency, can benefit from human growth hormone therapy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
